WIV press corner: The Belgian Institute of Public Health (WIV-ISP) participates in the development of a new vaccine against rabies and yellow fever.
KU leuven news site: KU Leuven to lead development of dual vaccine against yellow fever and rabies.
Twitter University of Leuven @LeuvenU
RABYD-VAX officially started its activities with the kick-off meeting held in Leuven, Belgium on the 11th of January 2017. This meeting was hosted by the University of Leuven (KU Leuven) at the Rega Institute for Medical Research, which is also the coordinator of this collaborative research project.
RABYD-VAX was created in response to a Horizon 2020 funded call by the European Commision’s Directorate-General Research and Innovation (SC1-PM-06-2016). This consortium gathers 5 institutional partners located in 3 European countries, namely the KU Leuven in Belgium (2 partners), the Belgian Scientific Institute of Public Health (Brussels), the Biomedical Primate Research Centre (BPRC) in The Netherlands and the Animal and Plant Health Agency (DEFRA/APHA) in the UK. The consortium has met for the first time to coordinate and plan its working activities over the next 4 years. In this timeframe RABYD-VAX aims to develop and validate a novel vaccine which targets both rabies and yellow fever virus or Zika or Japanese encephalitis virus, depending on the region of application.
To meet this main objective, the project has been organized in 8 work packages ranging from basic science in which novel constructs will be developed, studied for their immunity and efficacy, through to a development trajectory that will warrant the transition to advanced preclinical development.
During the meeting each work package leader and co-leaders had the opportunity to present their research topic and future planning, followed by intra-consortium discussions.
rabydvax.com 